Amylyx Pharmaceuticals, Inc.
AMLX
$14.44
-$0.44-2.96%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -14.97% | 12.11% | 52.70% | 42.99% | 69.77% |
| Total Depreciation and Amortization | -37.18% | -32.50% | -45.70% | -32.21% | -50.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 86.43% | -3.64% | -85.95% | -58.30% | -95.65% |
| Change in Net Operating Assets | 42.84% | 100.34% | 81.74% | 214.58% | -5,711.59% |
| Cash from Operations | 7.39% | 52.71% | 26.95% | 62.08% | -8,043.97% |
| Capital Expenditure | -- | 99.76% | -226.32% | 80.90% | 83.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 183.08% | -70.80% | -86.44% | 179.70% | -5,026.41% |
| Cash from Investing | 183.06% | -54.65% | -86.51% | 179.40% | -5,430.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 638.04% | 154.05% | 441.55% | 53.19% | -32.92% |
| Repurchase of Common Stock | -345.42% | -450.00% | -426.52% | -415.00% | 32.70% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -95.10% | -289.09% | 239,407.50% | -214.81% | 50,023.66% |
| Foreign Exchange rate Adjustments | -156.35% | 122.48% | -36.02% | 1,658.97% | 279.09% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 114.11% | -73.46% | 6,934.50% | 98.24% | -5,121.08% |